58 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves
8-K
EX-99.1
STRO
Sutro Biopharma Inc
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
for the year ended December 31, 2023 were comprised of research and development expenses of $180.4 million and general and administrative expenses of $62.6 … )
(In thousands, except share and per share amounts)
For the year ended December 31
Revenues
Operating expenses
Research and development
General
8-K
EX-99.1
y9ghy ti0druwy26s95z
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
fynj7nk80z b33
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
g5n67ed1ubt5434n
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
PRE 14A
o9ci6xu
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
ldcsmg8k 18148p1z
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm
8-K
EX-99.1
acc4ir754scclp80vyco
8 Nov 22
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
up5b2 jdi
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm